Nakagawa, Tatsuya
Tokuda, Yuichi
Nakano, Masakazu
Komori, Yuya
Hanada, Naoya
Tourtas, Theofilos
Schlötzer-Schrehardt, Ursula
Kruse, Friedrich
Tashiro, Kei
Koizumi, Noriko
Okumura, Naoki
Funding for this research was provided by:
Japan Society for the Promotion of Science (18K09464)
Japan Agency for Medical Research and Development (JP22ek0109590)
Article History
Received: 9 November 2022
Accepted: 18 May 2023
First Online: 27 May 2023
Competing interests
: Naoki Okumura and Noriko Koizumi are co-founders of ActualEyes Inc., which is currently developing a pharmaceutical therapy for treating Fuchs endothelial corneal dystrophy.